摘要: 介紹傳播動(dòng)力學(xué)模型在HPV疫苗藥物經(jīng)濟(jì)學(xué)評價(jià)中的應(yīng)用和計(jì)算方法，以期為更好的HPV疫苗經(jīng)濟(jì)性評價(jià)提供參考。將人群分為n個(gè)年齡組和L個(gè)性活動(dòng)層次，建立常微分方程組模擬HPV16/18兩種病毒感染在人群中的傳播和相關(guān)疾病的發(fā)生，并結(jié)合二價(jià)疫苗接種的保護(hù)效率對疾病預(yù)防健康產(chǎn)出進(jìn)行評估。傳播動(dòng)力學(xué)模型是動(dòng)態(tài)進(jìn)展模型，較Markov等靜態(tài)進(jìn)展模型模擬結(jié)果更符合實(shí)際，但也因?yàn)樾枰獏?shù)多，且部分關(guān)鍵參數(shù)在我國暫無大規(guī)模人群調(diào)研數(shù)據(jù)，因此用于經(jīng)濟(jì)學(xué)評價(jià)時(shí)證據(jù)質(zhì)量受到一定影響。在HPV疫苗等傳播性疾病干預(yù)產(chǎn)品的經(jīng)濟(jì)性評價(jià)中采用傳播動(dòng)力學(xué)模型以獲取更精確的證據(jù)，在目前參數(shù)不全的情況下，建議暫時(shí)以鄰國數(shù)據(jù)等方式替代。

Abstract: To provide a reference for economic evaluation on human papillomavirus (HPV) vaccine vaccination, we briefly introduced the application of transmission dynamics model in HPV vaccine vaccination economic evaluation and related calculation methods. In the transmission dynamics model-based evaluation on vaccination of bivalent HPV vaccine, the population is divided into various age groups and individual activity levels; an ordinary differential equation set is established to simulate the transmission of HPV16/18 virus infection in the population and the occurrence of related diseases; and the health output of disease prevention is calculated in combination with the protection efficiency of the vaccine. The transmission dynamics model is a dynamic progress model, which is more realistic than the simulation results of static progress models such as Markov. However, due to the lack of some key parameters and large-scale population survey data in China, the quality of the economic evaluation on HPV vaccine vaccination is affected to some extent. Considering on the absence of some parameters for the evaluation nowadays, some data from other countries could be utilized in transmission dynamics model-based economic evaluation on HPV vaccine vaccination to obtain more accurate analysis results.

[1]

Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses[J]. PLoS Medicine, 2006, 3(5): e138. DOI: 10.1371/journal.pmed.0030138

[2] 王玉, 陳姍姍, 傅新楚. 傳播動(dòng)力學(xué)模型回顧與展望[J]. 應(yīng)用數(shù)學(xué)與計(jì)算數(shù)學(xué)學(xué)報(bào), 2018, 32(2): 267 – 294. DOI: 10.3969/j.issn.1006-6330.2018.02.008 [3]

Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease[J]. Epidemio-logic Reviews, 2006, 28(1): 88 – 100. DOI: 10.1093/epirev/mxj006

[4] 郄素會. 宮頸癌疫苗用于18~25歲中國女性預(yù)防宮頸癌的藥物經(jīng)濟(jì)學(xué)評價(jià)[J]. 臨床醫(yī)藥文獻(xiàn)電子雜志, 2017, 4(48): 9342 – 9343, 9345. DOI: 10.3877/j.issn.2095-8242.2017.48.025 [5] 張倩. 子宮頸癌篩查的風(fēng)險(xiǎn)分流及疫苗的衛(wèi)生經(jīng)濟(jì)學(xué)評價(jià)研究[D]. 北京: 北京協(xié)和醫(yī)學(xué)院, 2017. [6] 孫雨欣, 劉永軍, 劉通. 宮頸癌疫苗用于18~25歲中國女性預(yù)防宮頸癌的藥物經(jīng)濟(jì)學(xué)評價(jià)[J]. 中國循證醫(yī)學(xué)雜志, 2017, 17(1): 102 – 107. DOI: 10.7507/1672-2531.201610004 [7] 莫秀婷. 我國宮頸癌預(yù)防策略的經(jīng)濟(jì)學(xué)評價(jià)[D]. 濟(jì)南: 山東大學(xué), 2015. [8] 劉怡君. HPV-16/18預(yù)防性疫苗的接種年齡對其預(yù)防子宮頸癌作用的衛(wèi)生經(jīng)濟(jì)學(xué)研究[D]. 大連: 大連醫(yī)科大學(xué), 2015. [9] 宋曉彬, 趙勤儉, 周鼒, 等. 二價(jià)HPV疫苗接種策略的衛(wèi)生經(jīng)濟(jì)學(xué)評估: 基于動(dòng)態(tài)模型[J]. 中華預(yù)防醫(yī)學(xué)雜志, 2017, 51(9): 814 – 820. DOI: 10.3760/cma.j.issn.0253-9624.2017.09.008 [10]

Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies[J]. Emerging Infectious Disease, 2007, 13(1): 28 – 41. DOI: 10.3201/eid1301.060438

[11]

Kermack WO, McKendrick AG. Contributions to the mathematical theory of epidemics: V. Analysis of experimental epidemics of mouse-typhoid; a bacterial disease conferring incomplete immu-nity[J]. Epidemiology and Infection, 1939, 39(3): 271 – 288.

[12]

Kermack WO, McKendrick AG. Contributions to the mathematical theory of epidemics-II. The problem of endemicity[J]. Bulletin of Mathematical Biology, 1991, 53(1): 57 – 87.

[13]

Wolff E, Elfstr?m KM, Haugen Cange H, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour[J]. Vaccine, 2018, 36(34): 5160 – 5165. DOI: 10.1016/j.vaccine.2018.07.018

[14]

Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination Programmes[J]. PharmacoEconomics, 2008, 26(3): 191 – 215. DOI: 10.2165/00019053-200826030-00004

[15]

Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries[J]. Vaccine, 2012, 30 Suppl 5: F157 – F167.

[16]

Tay SK, Hsu TY, Pavelyev A, et al. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis[J]. BJOG: An International Journal of Obstetrics and Gynaecology, 2018, 125(4): 478 – 486. DOI: 10.1111/1471-0528.15106

[17]

Damm O, Horn J, Mikolajczyk RT, et al. Cost-effectiveness of human papillomavirus vaccination in Germany[J]. Cost Effective-ness and Resource Allocation, 2017, 15: 18. DOI: 10.1186/s12962-017-0080-9

[18]

Largeron N, Petry KU, Jacob J, et al. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany[J]. Expert Review of Pharmacoe-conomics and Outcomes Research, 2017, 17(1): 85 – 98. DOI: 10.1080/14737167.2016.1208087

[19]

Mennini FS, Bonanni P, Bianic F, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy[J]. Cost Effectiveness and Resource Allocation, 2017, 15(1): 11. DOI: 10.1186/s12962-017-0073-8

[20]

Tang CH, Cheng WF, Jiang JH, et al. Cost-effectiveness analysis of human papillomavirus vaccination in adolescent girls in Taiwan[J]. Asian Pacific Journal of Cancer Prevention, 2019, 20(5): 1377 – 1387. DOI: 10.31557/APJCP.2019.20.5.1377

[21] 張師前, 王凱, 張遠(yuǎn)麗. HPV疫苗在中國的應(yīng)用現(xiàn)狀[J]. 中國實(shí)用婦科與產(chǎn)科雜志, 2019, 35(10): 1090 – 1095. [22] 國家藥品監(jiān)督管理局. 首個(gè)國產(chǎn)重組人乳頭瘤病毒疫苗獲批上市[EB/OL]. [2020 – 01 – 03]. http://www.nmpa.gov.cn/WS04/CL2056/373049.html. [23]

Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5[J]. Value in Health, 2012, 15(6): 828 – 834. DOI: 10.1016/j.jval.2012.06.011

相關(guān)知識

希瑞適成為中國首個(gè)兩劑次接種的HPV疫苗 HPV疫苗適用于9至14歲女孩
HPV疫苗有幾種？二價(jià)、四價(jià)和九價(jià)HPV疫苗有區(qū)別嗎
HPV疫苗惠民政策的區(qū)域探索及改善策略
關(guān)于HPV疫苗，你想知道的都在這里
中新健康丨HPV疫苗降價(jià)，單價(jià)低至百元以下
HPV疫苗知識大合集，你想知道的在這里！
云南某男子接種男性9價(jià)HPV疫苗，男性接種9價(jià)疫苗有用嗎？
感染HPV＝癌癥？15個(gè)問答，帶你了解為什么要接種HPV疫苗
HPV疫苗越早越小接種越好？專家：HPV疫苗能約幾價(jià)就打幾價(jià)
HPV疫苗相關(guān)知識問答

網(wǎng)址: 傳播動(dòng)力學(xué)模型在HPV疫苗經(jīng)濟(jì)學(xué)評價(jià)中應(yīng)用 http://www.u1s5d6.cn/newsview561916.html